Acme Universal Safezone9 IPO: A Real Factory Betting on Efficiency to Fill Idle Capacity

1. IPO Overview

Acme Universal Safezone9 Limited is listing on the BSE SME platform with a 100% fresh issue of up to 50,60,800 shares of face value Rs 10 each. There is no offer for sale, which means OFS, or shares sold by existing owners, is nil and no promoter is selling.

At the live band of Rs 65 to Rs 71 a share, the fresh raise is Rs 32.90 cr at the floor and Rs 35.93 cr at the cap, before issue expenses. The issue opens on September 28, 2026 and closes on September 30, 2026, with Expert Global Consultants as lead manager and Maashitla Securities as registrar.

Promoters held 94.66% before the issue and are not selling, while the public issue will constitute 26.50% of post-issue capital. Post-issue promoter percentage is not disclosed in the document, and lot size is also not disclosed. At the top of the band, Rs 71 a share, the company is valued at Rs 135.56 cr on post-issue shares, which implies 23.1x FY2025-26 reported profit and 1.5x book, with FY2025-26 return on net worth, or RoNW, which measures profit as a share of net worth, at 11.75%. The unusual point is that despite borrowings above net worth, none of the fresh money is earmarked for debt repayment.

2. What the company does

Acme makes industrial safety footwear under the brand ACME. Think of protective shoes for factory, construction, mining and oil plant workers, with steel toe caps, penetration-resistant soles, grip against slipping, and protection against chemicals, heat or electric shock.

The buyer is usually not the worker. Industrial groups, construction and infrastructure firms, oil and gas companies, automotive and logistics operators, public sector units and state buyers pay for the shoes, either directly or through distributors and dealers who reach smaller plants. The company earns money in a straightforward manufacturing way. It buys leather, rubber and polyurethane compounds, toe caps, laces and adhesives, cuts and stitches the upper, makes the sole, joins the two, tests the pair and sells the finished pair.

It runs four plants in Madhya Pradesh and Uttar Pradesh that cover the full chain in-house. Leather cutting happens in a dedicated area of about 25,000 sq ft, followed by upper stitching, lasting over a foot-shaped mould, sole injection, finishing and packing. Three German Desma direct-injection machines with robotic arms control sole density, while automated stitching machines control seam quality. An in-house laboratory tests each batch against Indian IS 15298, European EN ISO 20345 and American ASTM F2413 standards where applicable, and the plants run on SAP S/4 HANA for planning, stock, purchase, finance and logistics.

The catalogue spans 15 product lines across EVA-rubber, Nitrile Rubber and PVC soles. The core is general industrial safety shoes for manufacturing and construction, such as lightweight direct-injection models and triple-density anti-fatigue models. A second line is executive safety shoes that look formal but carry certified protection. A third is PVC and rubber boots for wet, chemical and high-temperature work in mining, foundries and oil and gas. A fourth is customised shoes for fit, branding or hazard-specific needs, designed with 3D visualisation tools. It also does custom development and OEM work, which means making shoes for select overseas brands, though no customer names or shares are disclosed.

Sales flow through three channels. Direct institutional sales use dedicated representatives and run on long-term rate contracts and annual agreements. A distributor and dealer network reaches industrial centres, backed by channel-partner warehousing at more than 40 locations including New Delhi, Mumbai, Pune, Hyderabad, Bengaluru, Chennai, Kolkata, Ahmedabad, Indore and Bhopal. Digital and e-commerce, including its website and B2B portals, handles enquiries and orders. Marketing includes trade fairs such as A+A Dusseldorf, OSH India and NSC Congress in the US, plus safety training at customer sites.

Scale remains domestic. In FY2025-26, domestic sales were Rs 190.17 crore, or 92.36% of revenue, exports were Rs 15.61 crore, or 7.58%, and SEZ sales were marginal. India alone was Rs 189.23 crore, or 91.90% of revenue, led by Maharashtra, Tamil Nadu, Gujarat, Uttar Pradesh and Odisha. Export markets include the UAE, Nigeria, Israel, Bahrain, Saudi Arabia, Netherlands, Hong Kong, Cameroon and Mauritius, but none exceeds 3.30% of revenue.

Concentration is material. The top customer was 12.13% of revenue in FY2025-26, 10.56% in FY2024-25 and 11.15% in FY2023-24, while the top 10 customers were 47.71%, 48.82% and 45.04% in those years. Buying is specification-driven and often on fixed-price rate contracts, with penalty clauses for late delivery illustrated at 0.5% per week capped at 5%. The document states the business is not seasonal.

What decides growth is whether Acme can fill its factories with repeat institutional orders, hold specifications and delivery, and manage leather and crude-linked compound costs under fixed selling prices. Capacity and working capital decide whether that growth turns into cash.

3. Use of Funds

The entire issue is fresh shares, so net proceeds go to the company, not to selling shareholders.

• Solar power plants of 1,080 KWp for Rs 3.62 crore across Gwalior, Banthar and Banmore to cut grid power cost
• Additional machinery for Rs 8.96 crore, including knife cutting, nesting, foam pouring and conveyor systems, to improve precision and cut wastage without raising overall installed capacity
• Incremental working capital up to Rs 8.00 crore, split as Rs 4.00 crore each in FY2026-27 and FY2027-28
• Inorganic growth through unidentified acquisitions and strategic initiatives plus general corporate purposes within regulatory caps

No amount is proposed for repayment of borrowings.

4. Financials Overview

The accounts are company-only, as the company states it has no subsidiary, so all profit belongs to the owners. Each column below is a full 12-month year ended March 31.

Revenue grew every year, up 4.70% in FY2025 and 9.90% in FY2026, but profit collapsed in FY2025 and only partly recovered in FY2026. Margins and returns swung sharply while leverage stayed above 1x. The detail behind that swing is in the next section.

5. What the financials tell us

Acme is a real operating factory that has just finished a large build. Sales are higher than two years ago, but the shoe operation itself earns very little, empty capacity weighs on cost, and growth absorbs cash funded by short-term debt that the IPO does not repay.

Most reported profit comes from extras, not shoes

The factory sells more pairs each year, yet core footwear earnings are thin. In FY2025, profit before tax was Rs 3.11 crore while other income was Rs 3.96 crore, which means other income was larger than total pre-tax profit and the shoe operation itself lost money that year.

In FY2026 the recovery was still flattered. Other income was Rs 5.26 crore against PAT of Rs 5.86 crore on the restated basis, or about nine-tenths of net profit. The document describes such income as including discounts, duty drawback and incentives. No product-wise sales, pairs sold or price per pair are disclosed, so pricing power cannot be checked. If those extras shrink or arrive late, reported profit can fall even if shoe volumes hold, as FY2025 showed.

A much bigger factory sits about one-third empty

The build is physically complete. Capital work-in-progress of about Rs 17.98 crore in FY2024 has become operating plant, with property, plant and equipment rising from Rs 30.79 crore to Rs 62.78 crore in two years.

Sales did not keep pace. Revenue rose from Rs 178.94 crore to Rs 205.90 crore, while soling volumes rose from 25,76,048 units to 27,71,851 units. Installed soling capacity was raised by about 30% to 43,15,000 units, so utilisation fell from 77.71% to 64.23%. At the same time depreciation more than doubled from Rs 4.64 crore to Rs 9.41 crore and employee benefits rose from Rs 23.91 crore to Rs 31.06 crore. Management links FY2025 to higher leather and rubber prices with limited pass-through, and FY2026 to softer input prices offset by new-plant depreciation and labour. The result is that clean EBITDA margin, which strips other income and is measured on revenue, at 7.36% in FY2026 remains below 8.13% in FY2024, and PAT remains about 23% below FY2024. Until sales fill the floor, each extra pair carries heavy fixed cost.

Selling more shoes leaves little cash in hand

Over three years the business generated more operating cash than accounting profit and paid no dividends, so cash did not leak to promoters. That discipline is a strength for a manufacturer that must buy leather, rubber and chemicals upfront.

But FY2026 shows why profit does not equal cash. Operating profit before working-capital changes was Rs 19.67 crore, yet cash generated from operations was only Rs 10.30 crore, with almost half absorbed. Higher inventories used Rs 3.97 crore and higher other current assets used Rs 4.14 crore. Raw-material stock rose from Rs 14.35 crore to Rs 18.32 crore, faster than sales, while balances with government authorities rose from Rs 6.70 crore to Rs 10.42 crore. Some stock build is normal, but the GST-type lock-up plus inventory meant profit growth did not arrive as cash. The company also spent Rs 12.65 crore on plant in FY2026 alone, leaving free cash negative in every one of the last three years.

The company will still owe a lot after listing

Borrowings exceed net worth and almost all of it is due within a year. Total borrowings were Rs 58.05 crore as at March 31, 2026, split as Rs 13.84 crore long-term and Rs 44.21 crore short-term, against equity of Rs 52.77 crore.

Cash credit jumped from Rs 15.30 crore to Rs 27.01 crore in FY2026 while long-term loans were repaid on a net basis, with Rs 9.80 crore of net short-term borrowing funding the gap. About Rs 13.39 crore is unsecured loans from promoters, or about one-quarter of net worth, shown as short-term with no rate disclosed, and bank debt carries promoter personal guarantees. Interest paid in FY2026 was Rs 3.18 crore, or over two-fifths of operating cash, while cashwas only Rs 89.41 lakhs. Since no IPO object is debt repayment, this short-term funding mix and rollover risk stay after listing.

One large order or one unpaid bill can swing the year

Sales and purchases are concentrated. The top customer was Rs 24.98 crore, or 12.13% of revenue in FY2026, and the top 10 were Rs 98.23 crore, or 47.71%. The top 10 suppliers were 52.88% of purchases, with the largest at 15.92%. With thin core margins and fixed-price contracts, losing an institutional order or facing an input spike can move profit materially.

Small-supplier dues add a separate risk. Principal unpaid to MSME suppliers is shown at Rs 22.52 crore, almost double the Rs 11.26 crore shown as micro-enterprise payables on the balance sheet and over 40% of net worth. No interest is shown as unpaid in FY2026 after two years of unpaid interest, alongside disclosed delays in GST, ESI, PF and ROC filings. If delayed-payment interest rules apply, the charge would fall directly on already-thin core earnings and cash.

6. Valuation Analysis

For a profitable manufacturer, the natural lens is earnings multiple, but here reported earnings and shoe earnings tell different stories, so both must be shown. At the top of the band, Rs 71 a share, market capitalisation on post-issue shares is Rs 135.56 cr, with price to book, or P/B, which compares market value to net worth, at 1.5x and post-issue NAV, or net asset value per share, at Rs 46.46, against pre-issue NAV of Rs 37.60.

On reported FY2025-26 profit of Rs 5.86 cr, post-issue P/E, which shows how many years of profit the price pays for, is 21.2x at Rs 65 and 23.1x at Rs 71. On profit stripped of other income, the same price implies 64.7x at the floor and 70.7x at the cap. The pre-issue P/E on restated basic EPS of Rs 4.17 is 15.6x to 17.0x, but that ignores dilution and flatters the buyer.

Peers on the document's July 2026 snapshot trade at 20.76x for Mallcom, 40.82x for Liberty and 54.74x for Superhouse, with a median of 40.82x and average of 38.77x. Acme therefore screens at a 43% to 48% discount to the median on reported earnings, but at a 59% to 73% premium on core earnings. The discount is not earned because it rests on incentive-led profit, while the core premium is not earned because Acme trails on margins, returns and leverage without faster growth. Paying low-twenties for reported earnings means paying high-sixties for the shoe business itself, with idle capacity and short-term leverage intact.

7. Peer Analysis

Basis: Acme P/E uses band Rs 65-71 on post-issue shares over FY2025-26 reported PAT; peers use FY2026 audited consolidated EPS over BSE close on July 27, 2026 as printed in the document.

Source: RHP — Comparison of our key performance indicators with listed industry peers; pages 93-94. Basis: audited consolidated basis. Calculated from the RHP's revenue figures; every other cell is as printed.

Mallcom was the fastest grower over FY2024 to FY2026 at 28.4%, followed by Liberty at 16.2% and Acme at 15.1%, with Superhouse flat at 2.7%. In FY2026 alone Acme re-accelerated to 9.90% after 4.70%, Liberty was steady at 9.55%, Mallcom slowed to 4.77% after a strong FY2025, and Superhouse stalled. Margin pressure was industry-wide except for Superhouse off a low base, but levels differ sharply. Acme EBITDA margin fell from 8.13% to 7.36%, Liberty from 10.54% to 8.69%, Mallcom from 13.71% to 11.19% yet stayed highest, while Superhouse edged from 5.55% to 6.05%. Acme PAT margin rebounded from 0.43% to 2.84% but remains below 4.23% in FY2024, and RoCE at 5.54% trails Mallcom at 11.28% and Liberty at 9.92%.

The businesses are not identical. Acme is a pure-play safety-footwear maker at about Rs 205.9 crore revenue. Liberty at about Rs 740 crore is broader consumer footwear where safety is one division, Superhouse at about Rs 683 crore is diversified leather to footwear and goods, and Mallcom at about Rs 540 crore is head-to-toe PPE with over 1,000 SKUs and the closest fit. Acme runs four plants with Desma automation and SAP, but utilisation is only 64.23% after expansion, while peers run 11 to 22 plants with wider automation and sustainability platforms. Acme is leaner on working capital with a 75-day operating cycle versus 154 to 225 days for peers, yet far more leveraged at 1.10x debt to equity versus 0.34x to 0.39x, with interest cover of 1.80x versus 5.87x for Mallcom.

On customers, Acme is institutional and distributor-led with persistent top-10 concentration near 48% and India at 91.90% of sales, plus fixed-price rate contracts that limit pass-through. Peers sell through 500-plus retail points, 70-plus dealers and 50-plus countries across hazard categories, implying more diversified demand. On financials, Acme is smallest and most volatile, with EBITDA at 7.36% versus 11.19% for Mallcom and 8.69% for Liberty, and RoNW swinging from 19.82% to 1.81% to 11.75%. Peers share cyclicality but do not share Acme's combination of other income at about 90% of PAT, doubled depreciation on half-empty capacity, debt above equity with no IPO deleveraging, negative free cash every year, and large MSME and promoter dues.

Peer figures here come from the peers' own disclosures except the growth and profitability table where both sides come from the offer document on restated basis for Acme and audited consolidated basis for peers. Overall, the asking price is not earned against peers, with Mallcom growing faster at higher margins and returns, lower leverage and a cheaper 20.76x multiple as the anchor.

8. Moat

What sets Acme apart is control over the whole shoe inside one system. Cutting, stitching, lasting, sole injection, testing and packing stay in-house, with batch test records and multi-standard compliance that let the same lines serve domestic institutions and export buyers. Desma injection brings consistency in sole density, Orisol stitching brings seam consistency, and SAP links planning, stock and dispatch across plants. Warehousing through more than 40 channel locations helps reach industrial belts quickly.

These are real advantages over small workshops, but they are modest moats. The plants are leased, including key factories leased from promoters, automation and ERP can be bought by rivals, and triple-density or Phylon processes are process know-how rather than patented barriers. Single infrastructure for Indian and global standards needs tooling and approvals, yet larger peers already operate similar multi-standard systems at greater scale.

Tailwinds help all compliant makers, not Acme alone. Safety use is mandated across construction, oil and gas, mining and heavy industry, which sustains institutional demand for its 15 lines. Rising worker-safety awareness and BIS certification shift buying toward organised brands in tenders and GeM orders. Make in India and PLI-linked manufacturing support domestic capacity and import substitution. The industry source cited is D&B.

Durability is therefore limited. As long as BIS licences stay valid and delivery holds, Acme can keep rate contracts, but any rival with BIS, EN ISO and testing can contest the same tender. If utilisation stays in the low-60s and input prices spike under fixed selling prices, efficiency from new cutting and solar plant must carry margins. Without filling capacity and widening exports beyond 7.58%, the edge remains operational competence rather than a lasting moat.

9. Risks

• Demand and customer concentration. The top 10 buyers drive about 48% of revenue and the top buyer exceeds 10% every year, so loss of one account can disrupt sales and margins. This is idiosyncratic to Acme versus broader peers, and it persisted across FY2024 to FY2026 even as new customers were added.
• Funding and working-capital strain. Borrowings of Rs 58.05 crore exceed net worth, almost all short-term, with a 75-day cycle and net working capital near Rs 49.78 crore. Cash credit funded growth while interest took over two-fifths of operating cash. The Rs 8 crore IPO working-capital support helps only partly, and leverage is industry-high versus peers. This risk rose as the cycle lengthened from 65 to 75 days.
• Certification and tender eligibility. Loss of BIS IS 15298 or other quality approvals would immediately disqualify government, GeM and defence orders. Licences are currently valid with in-house testing, but EPCG export obligations run to November 2030 and failure risks duty clawback. This is partly industry-wide, but Acme's domestic concentration makes it more exposed.
• Input costs without pass-through. Material consumed was 69.51% of total income in FY2026, with leather and crude-linked compounds volatile and no long-term fixed-price supplier deals, while rate contracts fix selling prices. EBITDA margin at 7.36% leaves little buffer. Peers also compressed, but Acme's FY2025 core loss shows higher sensitivity.
• Collections and supplier payments. Receivables were Rs 28.80 crore, though about 97% was later recovered, and MSME principal dues of Rs 22.52 crore dwarf balance-sheet micro payables with repeated filing delays. Any enforcement of interest or slower collection would hit cash and thin core earnings directly.

Governance flags include Rs 13.39 crore of promoter loans, promoter-leased factories, trademark oppositions on four ACME marks, and record errors including ROC and director-name mismatches. Contingent guarantees of Rs 48.52 lakhs and disputed tax of Rs 85 lakhs are small against net worth.

10. Verdict

The call rests on four load-bearing facts. Core shoe earnings are a fraction of reported profit, with other income near nine-tenths of PAT. Expanded soling capacity sits at 64.23% utilisation while depreciation has doubled. Borrowings exceed equity, are almost all short-term, and the IPO repays none. And nearly half of sales depend on 10 customers while over half of purchases depend on 10 suppliers.

Together they mean the buyer pays 21x to 23x for incentive-led earnings but 65x to 71x for shoe earnings, without superior growth, margins, returns or leverage to justify a premium to peers like Mallcom. For the thesis to work, new cutting and solar kit must lift throughput and per-pair cost enough to fill idle capacity and stabilise core margins through input cycles. It would break if utilisation stays soft, a key customer or supplier slips, BIS eligibility lapses, or MSME interest and rollover costs absorb operating cash.

11. IPO Snapshot